Advancing promising therapies for rare diseases
Our mission: “To deliver impactful therapies to treat rare diseases with limited or no treatment options.”
At Mereo BioPharma, we navigate the complexities of rare disease drug development to deliver therapies to the people who need them most. We do this in a capital-efficient manner. Central to our mission is working with patient organizations, physicians and healthcare systems so that we advance promising therapies for rare diseases.
Discover our pipeline of novel therapeutic candidates
Mereo BioPharma was founded in 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies for strategic reasons.
Our programs have already received significant capital investment from the originator pharmaceutical or biotechnology company, including in clinical development.
The Mereo pipeline is focussed on our two lead rare disease programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). In addition, we have out-licensed several other clinical stage programs.
We operate with a capital efficient model
We operate a capital efficient model and form strategic partnerships including for non-dilutive capital where it makes sense to do so, while retaining European, or U.S. and rest of the world rights to maintain future value and optionality.
Supporting patients and communities
We understand that patients are not just participants in the healthcare journey; they are experts in their own conditions. This is especially true in the rare disease space, where lived experience often surpasses clinical understanding.
That’s why we actively collaborate with people living with rare conditions, caregivers, and community groups throughout the development process. We believe that, by listening to and learning from the patient community, we can drive more meaningful progress and deliver treatments that have a real and lasting impact.
In February 2025, Mereo and our partner Ultragenyx were the proud recipients of the Black Pearl Company Award for Patient Engagement. This prestigious award recognizes companies’ commitment to serving and empowering people living with rare conditions through meaningful collaboration.
Osteogenesis imperfecta (OI)
OI is a rare genetic bone condition that affects children and adults. We actively engage with the OI community and related organizations at both local, national and international levels to ensure we truly understand their perspectives and priorities.
Alpha-1 Antitrypsin Deficiency–associated Lung Disease (AATD-LD)
AATD is a rare genetic condition that results in a deficiency of alpha-1 antitrypsin. We engage with local, national and international Alpha-1 community representative organizations and support groups because we understand the importance of gaining first-hand insights into the experiences of people living with AATD-LD.
Every person at Mereo is driven by a shared purpose: to work toward a future where people and families with rare diseases, especially those with few or no treatment options, have access to therapies that can transform their lives.
We’re a team of passionate thinkers, collaborators, and changemakers. If you’re looking for more than a job, if you want your work to matter, Mereo is where you can make a real difference.
Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across the pharmaceutical and biotechnology industry.
Join a team where your work truly matters, your voice is heard, and your impact is real.